Vedbaek, Denmark

Michi Egel-Mitani


Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 170(Granted Patents)


Location History:

  • Vedb.ae butted.k, DK (1999 - 2000)
  • Vedbæk, DK (2001)
  • Vedbaek, DK (2009 - 2014)

Company Filing History:


Years Active: 1999-2014

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Michi Egel-Mitani: Innovator in Acylated Polypeptide Technologies

Introduction

Michi Egel-Mitani, an accomplished inventor based in Vedbaek, Denmark, holds eight patents in the field of biochemistry and molecular biology. His innovative spirit and contributions to the scientific community have made significant advancements in the production of acylated polypeptides.

Latest Patents

Among his latest inventions is a method for making acylated polypeptides. This cutting-edge technology involves producing polypeptides in transformed host cells by expressing a precursor molecule which is subsequently acylated in an in vitro step. The invention encompasses DNA sequences, vectors, and transformed host cells essential for the claimed method. Notably, Egel-Mitani's work details particular precursors and acylation methods that allow for preferential acylation in certain lysine ε-amino groups, thus enhancing the efficacy of the polypeptides produced.

Career Highlights

Egel-Mitani is currently employed at Novo Nordisk A/S, a leading global healthcare company known for its focus on diabetes care and hormone replacement therapies. His role in the company has facilitated groundbreaking research and development in biopharmaceuticals, contributing to the advancement of therapeutic proteins.

Collaborations

Throughout his career, Michi Egel-Mitani has enjoyed successful collaborations with notable professionals in his field, including Per Balschmidt and Jan Markussen. These partnerships have further enriched his innovative processes and production techniques in the realm of polypeptide development.

Conclusion

Michi Egel-Mitani exemplifies the spirit of innovation in biochemistry with his significant contributions to the understanding and production of acylated polypeptides. His work not only enhances scientific knowledge but also paves the way for the development of new therapeutic options in medicine. With a solid foundation of patents and collaborations, Egel-Mitani continues to be a valuable asset to the Novo Nordisk A/S team and the scientific community at large.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…